Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved ribociclib (Kisqali, Novartis) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, HER2-negative stage II and III early breast cancer at high risk for recurrence. The FDA also approved the ribociclib and letrozole co-pack (Kisqali Femara Co-Pack, Novartis) for the same indication.
Efficacy of ribociclib with a nonsteroidal